British firm Rem3dy Health has announced a strategic investment from Hikma Ventures, the corporate venture capital arm of London-listed pharmaceutical group Hikma Pharmaceuticals PLC (Hikma).
The investment — the amount of which remains undisclosed — will allow Rem3dy to introduce its 3D-printed supplements across seven markets in the Middle East and North Africa (MENA) region, using Hikma's established regional distribution network.
The company said that initial launches were planned for the UAE, Saudi Arabia and Jordan in the first quarter of next year, with further expansion planned across Qatar, Kuwait, Oman and Bahrain.
Rem3dy — a UK-based health technology and manufacturing company — was founded in 2019 by entrepreneur Melissa Snover.
The firm comprises two brands: Nourished, a personalised nutrition brand and Scripted, a division focused on personalised medicine.
Rem3dy has invested significantly in developing and scaling its manufacturing capabilities in the West Midlands, creating an advanced production platform that supports both personalised nutrition and an expanding range of retail and commercial products.
It uses patented 3D printing, AI and material science to produce customisable nutritional supplements at commercial scale, enabling multiple active ingredients to be combined into a single seven-layer nutritional gummy.
Rem3dy's growth has so far been robust — in June, the firm closed a £14m funding round at an £84m valuation and its 2025 revenue climbed 61% year-on-year to £10.2m.
Now, using these funds, the company is looking to expand into new markets such as the MENA region, India and the US.
This latest agreement builds on Hikma's commitment to commercialising an exclusive selection of Nourished's 3D-printed vitamins, minerals, health supplements, specialist foods and natural beauty solutions, announced last month.
The products will form the foundation of Hikma's Vitamins, Minerals and Supplements (VMS) portfolio as it looks to expand into the nutraceutical sector.
The Nourished products developed for Hikma will be manufactured in the UK and initially focus on cognitive wellbeing, gut health, hair and nail health and sleep.
Melissa Snover, founder and CEO of Rem3dy Health, said: "Having Hikma invest in Rem3dy as well as partner with us commercially is particularly meaningful because it connects capital investment with a genuine route to market."
"We have spent the past seven years developing our technology, building our intellectual property and scaling our manufacturing capabilities here in Birmingham."
This partnership gives us the opportunity to take products developed and manufactured in the UK into new international markets, supported by the expertise and reach of one of the world's most established pharmaceutical businesses.
"It is a significant milestone for our team and a great example of how British innovation and advanced manufacturing can create opportunities for international growth."
Lana Ghanem, Vice President Corporate Development at Hikma Pharmaceuticals and Managing Director of Hikma Ventures, added: "At Hikma, we are constantly looking for innovative companies that are shaping the future of healthcare."
Rem3dy Health combines differentiated technology, strong consumer engagement and a compelling vision for personalised wellness.
"This investment reflects Hikma Ventures' strategy of backing high-growth healthcare businesses that not only have significant commercial potential but can also create strategic value across Hikma's businesses and markets."
